Compare Mesoblast Limited (MESO) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs ProShares UltraPro S&P500 — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while ProShares UltraPro S&P500 trades at $140.25. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | UPRO | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $20.96 | $150.93 |
52-Week Low | $12.88 | $89.29 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
UPRO trades at $138.50, down 0.4% on the day, with a bearish technical signal driven by moving averages. Key support lies at $135, while resistance is at $141. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights S&P 500 concentration risks and AI-driven market volatility, influencing this leveraged ETF's performance.
The outlook is cautious due to technical weakness and broader market concerns over valuation and tech stock reliance. Risks include market corrections and ETF-specific volatility. Investors should weigh the lack of fundamental data against the leveraged exposure to S&P 500 trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
